Lung Cancer Europe shared a post on LinkedIn:

“NEW LuCE MEMBER: Alk+ France cancer poumon

We are very happy that Alk Ros1 France Cancer Poumon has become a member of Lung Cancer Europe (LuCE).

Alk+ France cancer poumon is a group of patients affected by lung cancer with ALK or ROS1 rearrangement, rare pathologies representing 1 to 5% of non-small cell lung cancers (NSCLC).

Their objectives are to:

• Raise awareness of these rare and little-known forms of lung cancer
• Support patients in their care journey and inform them about the disease
• Interact with healthcare professionals specializing in the field to stay informed of the best available and upcoming therapeutic options
• Encourage research into the development of new treatments, synonymous with hope and quality of life
• Represent ALK and ROS1 patients in professional and decision-making bodies and ensure that everyone has access to the latest therapeutic advances regardless of their geographical position in the territory
• Raise funds to achieve our objectives, finance communications tools and activities for the benefit of patients.They have approximately 300 members including:
•  Valerie Montagny – President
•  Sandrina Alliaume – Secretary
•  Anne Laurence Coursier and Adeline Chocarelle – International Relations TeamWe take great pride in welcoming them and their members to LuCE and look forward to working with the organisation on all of our shared objectives.”

Source: Lung Cancer Europe/LinkedIn